The vitamin D5 series of compounds are different from the D3 series. In vitamin D5, there is an ethyl group at the C-24 position. Earlier, we showed that an analog of vitamin D5, 1alpha-Hydroxyvitamin D5 (1alpha(OH)D5), is relatively nontoxic and non-calcemic compared to other vitamin D analogs (1). During the past 2 years of the funding period, we have shown that 1alpha(OH)D5 was effective in inhibiting both the tumor incidence and multiplicity of MNU- and DMBA-induced mammary carcinogenesis in rats. We also showed that the effect of 1alpha(OH)D5 was more prominent during the promotion phase of carcinogenesis. Here we will evaluate efficacy of 1alpha(OH)D5 in clinically relevant experimental protocol either singly or in combination with tamoxifen. More recently, the gene array profile of normal and transformed human mammary epithelial cells suggested that, among the differentially expressed genes, prohibitin, a cell cycle regulatory gene was upregulated in transformed cells. Moreover, prohibitin was down-regulated when transformed cells were treated with 1alpha(OH)D5. This provides a clue for understanding D5-mediated cell cycle regulation in transformed cells. We hypothesize that, in addition to vitamin D receptor, prohibitin may be an essential target for the action of 1alpha(OH)D5 in chemoprevention. Very little has been reported regarding the metabolism and pharmacokinetics of the D2, D4, and D5 series of vitamin D analogs. Recently, Jones and colleagues reported that C24 methyl or ethyl might be a metabolic determinant for vitamin D4 and D5 analogs (2). Dr. Glenville Jones will collaborate with us on this project to evaluate metabolism of 1alpha(OH)D5 in normal and neoplastic breast cells and tissues. Understanding of both the mechanism of action and metabolism of 1alpha(OH)D5 is crucial in developing this analog for clinical application. The following specific aims are proposed to determine: 1. Whether 1alpha (OH)D5 prevents development of tumors subsequent to surgical excision of the first palpable tumor? Whether the combination of 1alpha(OH)D5 and tamoxifen provide enhanced protection compared to either agent alone? 2. Whether prohibitin plays a role in cell transformation and chemopreventive efficacy in these cells? 3. How is 1alpha(OH)D5 metabolized in normal and neoplastic mammary epithelial cells and tissues?

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
7R01CA082316-05
Application #
6802724
Study Section
Metabolic Pathology Study Section (MEP)
Program Officer
Kim, Young Shin
Project Start
2000-05-15
Project End
2007-08-31
Budget Start
2004-09-15
Budget End
2005-09-14
Support Year
5
Fiscal Year
2004
Total Cost
$297,843
Indirect Cost
Name
Iit Research Institute
Department
Type
DUNS #
005447826
City
Chicago
State
IL
Country
United States
Zip Code
60616
Mehta, Rajendra G; Peng, Xinjian; Alimirah, Fatouma et al. (2013) Vitamin D and breast cancer: emerging concepts. Cancer Lett 334:95-100
Alimirah, Fatouma; Vaishnav, Avani; McCormick, Michael et al. (2010) Functionality of unliganded VDR in breast cancer cells: repressive action on CYP24 basal transcription. Mol Cell Biochem 342:143-50
Peng, Xinjian; Vaishnav, Avani; Murillo, Genoveva et al. (2010) Protection against cellular stress by 25-hydroxyvitamin D3 in breast epithelial cells. J Cell Biochem 110:1324-33
Peng, Xinjian; Hawthorne, Michael; Vaishnav, Avani et al. (2009) 25-Hydroxyvitamin D3 is a natural chemopreventive agent against carcinogen induced precancerous lesions in mouse mammary gland organ culture. Breast Cancer Res Treat 113:31-41
Peng, Xinjian; Mehta, Rajendra G (2007) Differential expression of prohibitin is correlated with dual action of Vitamin D as a proliferative and antiproliferative hormone in breast epithelial cells. J Steroid Biochem Mol Biol 103:446-50
Murillo, Genoveva; Matusiak, Damien; Benya, Richard V et al. (2007) Chemopreventive efficacy of 25-hydroxyvitamin D3 in colon cancer. J Steroid Biochem Mol Biol 103:763-7
Peng, Xinjian; Jhaveri, Pavan; Hussain-Hakimjee, Erum A et al. (2007) Overexpression of ER and VDR is not sufficient to make ER-negative MDA-MB231 breast cancer cells responsive to 1alpha-hydroxyvitamin D5. Carcinogenesis 28:1000-7
Murillo, Genoveva; Mehta, Rajendra G (2005) Chemoprevention of chemically-induced mammary and colon carcinogenesis by 1alpha-hydroxyvitamin D5. J Steroid Biochem Mol Biol 97:129-36
Peng, Xinjian; Mehta, Rajendra G; Tonetti, Debra A et al. (2005) Identification of novel RARbeta2 transcript variants with short 5'-UTRs in normal and cancerous breast epithelial cells. Oncogene 24:1296-301
Matusiak, Damien; Murillo, Genoveva; Carroll, Robert E et al. (2005) Expression of vitamin D receptor and 25-hydroxyvitamin D3-1{alpha}-hydroxylase in normal and malignant human colon. Cancer Epidemiol Biomarkers Prev 14:2370-6

Showing the most recent 10 out of 14 publications